Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
$0.38
-0.1%
$0.35
$0.22
$3.09
$22.21M1.481.48 million shs1.16 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
0.00%-0.50%-2.57%-2.85%-87.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
2.3688 of 5 stars
3.05.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
2.00
Hold$3.39802.86% Upside

Current Analyst Ratings Breakdown

Latest ELEV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/10/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
6/10/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral
6/9/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/9/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/A$1.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%8/5/2025 (Estimated)

Latest ELEV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$0.26N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$0.20-$0.24-$0.04-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
0.67
19.40
19.40

Institutional Ownership

CompanyInstitutional Ownership
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
83.70%

Insider Ownership

CompanyInsider Ownership
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
8.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
4059.22 million54.43 millionOptionable

Recent News About These Companies

Concentra buys out another struggling Boston biotech
Elevation Oncology agrees to be acquired by Concentra

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elevation Oncology stock logo

Elevation Oncology NASDAQ:ELEV

$0.38 0.00 (-0.05%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.38 0.00 (0.00%)
As of 07/18/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.